This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Astrazeneca Ab. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Gail Wrigley: Innovator in Cancer Therapy
Introduction
Gail Wrigley is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of cancer therapy through her innovative research and development of pharmaceutical compounds. Her work focuses on the inhibition of DNA polymerase theta, a critical enzyme involved in cancer cell proliferation.
Latest Patents
Gail Wrigley holds a patent for POLQ inhibitors, which are compounds designed to target and inhibit the activity of DNA polymerase theta (Polθ or POLQ). The specification of her patent generally relates to compounds of Formula (I) or their stereoisomers or pharmaceutically acceptable salts. These compounds are particularly useful in the treatment of cancer, providing new avenues for therapeutic intervention.
Career Highlights
Wrigley has had a successful career at AstraZeneca AB, where she has been instrumental in advancing cancer treatment options. Her research has led to the development of innovative compounds that have the potential to improve patient outcomes in oncology.
Collaborations
Gail Wrigley collaborates with esteemed colleagues, including Sofia Ferrer Cabrera and Helen Elizabeth Jones. These partnerships enhance the research and development process, fostering innovation in the pharmaceutical industry.
Conclusion
Gail Wrigley's contributions to cancer therapy through her patent for POLQ inhibitors exemplify her dedication to advancing medical science. Her work continues to inspire future innovations in the field of oncology.